Loading organizations...
Adendra Therapeutics is a pre-clinical biotechnology company based in Potters Bar, United Kingdom, that discovers and develops novel immunotherapies for solid cancers and T-cell-based autoimmune diseases by targeting dendritic cell immune responses. The firm applies scientific research on how dendritic cell receptors regulate adaptive immunity to effectively modulate and control the human immune system's response to tumors. The venture-backed enterprise officially emerged from stealth operations with a $53 million Series A financing round provided entirely by the life sciences venture capital firm Apple Tree Partners. Operating as an institutional spinout originating from The Francis Crick Institute, the organization was subsequently recognized with the New Startup of the Year Award from Cancer Research Horizons. Adendra Therapeutics was founded in 2021 by Francis Crick Institute professor and immunologist Caetano Reis e Sousa alongside chief executive officer Raj Mehta.
Adendra Therapeutics has raised $53.0M across 1 funding round.
Adendra Therapeutics has raised $53.0M in total across 1 funding round.
Adendra Therapeutics has raised $53.0M across 1 funding round. Most recently, it raised $53.0M Series A in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $53M Series A | RAJ Mehta | Joseph A. Yanchik III, Michael Ehlers, ATP (apple Tree Partners) | Announced |
Adendra Therapeutics has raised $53.0M in total across 1 funding round.
Adendra Therapeutics's investors include Raj Mehta, Joseph A. Yanchik III, Michael Ehlers, ATP (Apple Tree Partners).
Adendra Therapeutics is a biotechnology company developing novel immunotherapies that modulate dendritic and other immune cells to treat solid tumors and autoimmune diseases.[1][2][6] It builds small molecule and biologic medicines based on insights into dendritic cell biology, targeting immunological control of cancer and T cell-driven autoimmunity, primarily serving patients with hard-to-treat cancers and autoimmune conditions.[2][3][6] The company solves unmet needs in oncology and immunology by augmenting immune responses where current therapies fall short, with early momentum from its 2021 spin-out status and backing by accelerator ATP, positioning it for preclinical advancement.[2]
Adendra Therapeutics emerged in 2021 as a spin-out from The Francis Crick Institute's Immunobiology Laboratory, led by Professor Caetano Reis e Sousa, in collaboration with Raj Mehta, Ph.D., an Entrepreneur-in-Residence at ATP (Atlas Venture's therapeutics accelerator).[2] Mehta, who previously founded GammaDelta Therapeutics (acquired by Takeda) and Revitope Oncology, co-founded Adendra and serves as CEO, bringing expertise in immunotherapy development.[2] ATP launched the company to translate Reis e Sousa's pioneering dendritic cell research into therapeutics, marking ATP's first UK-based venture; it was formally incorporated on August 10, 2021, as a private limited company focused on biotechnology R&D (SIC 72110).[2][4] Early traction stemmed from this academic-industry partnership, enabling rapid setup in Potters Bar, UK.[2][4]
Adendra stands out in immunotherapy through:
Adendra rides the wave of next-generation immunotherapies, shifting from broad checkpoint inhibitors to cell-specific modulation amid rising solid tumor resistance and autoimmune prevalence.[1][2][6] Timing aligns with post-2020 advances in dendritic cell biology, fueled by AI-driven discovery and mRNA vaccine lessons, positioning it favorably in a $100B+ oncology/immunology market growing 8-10% annually.[2] Market forces like regulatory emphasis on precision immunology (e.g., FDA/EMA fast-tracks) and investor interest in UK biotechs bolster it; Adendra influences the ecosystem by validating academic spin-outs and ATP's transatlantic model, potentially spawning follow-on ventures in Europe.[2][4]
Adendra is primed for Series A funding and IND-enabling studies by 2026-2027, with lead candidates targeting high-need solid tumors like melanoma or lung cancer and autoimmune indications like rheumatoid arthritis.[2][4] Trends in multimodal immunotherapies and combination regimens will shape its path, amplifying dendritic modulation's role in overcoming resistance. Its influence may evolve from early-stage innovator to pipeline leader, especially if ATP's network secures partnerships with big pharma, echoing GammaDelta's Takeda success—ultimately redefining immunogenicity tuning for intractable diseases.[2] This positions Adendra as a high-upside bet in precision biotech.
